{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"7.6","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Time to response was defined as the time from the first dose to the first documentation of response (PR or CR). Per planned analysis, time to response by ICR was assessed for the TNBC Target Population only.","dispersionType":"Full Range","groups":[{"description":"Overall 144 participants with TNBC were enrolled in the study and received at least one dose of SG. Of these 144 participants, 108 received at least 2 prior therapies for metastatic disease and were treated with SG at a starting dose of 10mg/kg. These 108 participants were included in the analysis of safety and were referred to as the TNBC Target Population.","id":"OG000","title":"TNBC Target Population"}],"paramType":"MEDIAN","populationDescription":"Target mTNBC: Participants with mTNBC who received at least 2 prior therapies for metastatic disease \\& who received at least 1 dose of 10 mg/kg SG","reportingStatus":"POSTED","timeFrame":"Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)","title":"Time to Response by ICR","type":"SECONDARY","unitOfMeasure":"months"}